Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Yaniv Kazansky(Memorial Sloan Kettering Cancer Center), Alex Kentsis(Memorial Sloan Kettering Cancer Center), Daniel Cameron(Memorial Sloan Kettering Cancer Center), Phillip Demarest(Memorial Sloan Kettering Cancer Center), Romel Somwar(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Andrew L. Kung(Memorial Sloan Kettering Cancer Center), Filemon S. Dela Cruz, Noemi Arrighetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Rui Qu(Memorial Sloan Kettering Cancer Center), Yasumichi Kuwahara(Kyoto Prefectural University of Medicine), Valentina Zuco(Fondazione IRCCS Istituto Nazionale dei Tumori), Helen S. Mueller(Memorial Sloan Kettering Cancer Center), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center)
Cited by 47
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k